Abduljawad Mohammad, Alsharif Thamer H, Gronfula Amin G, Magadmi Talah K, Khayat Lujain I, Fageeh Sarah M, Almuallim Abdulqader A, Mohammad Mohammad Ayman, Albadri Abdullah
Dermatology, King Fahad General Hospital, Jeddah, SAU.
Neurosurgery, Royal College of Surgeons in Ireland, Dublin, IRL.
Cureus. 2023 Jun 29;15(6):e41125. doi: 10.7759/cureus.41125. eCollection 2023 Jun.
Anti-interleukin-17A (anti-IL-17A) therapy has been increasingly employed as a treatment option for pityriasis rubra pilaris (PRP). In this study, we reviewed all available studies on this topic in the literature to evaluate the efficacy and safety of anti-IL-17A. Our main objective was to assess the current evidence on the efficacy and safety of anti-IL-17A therapy in the management of PRP. We searched for relevant articles on PubMed, MEDLINE, Ovid, Embase, and the Web of Science electronic databases from inception until 2022. Our inclusion criteria were as follows: randomized controlled trials (RCTs), quasi-randomized trials, or prospective observational studies that include PRP patients treated with biological treatments; studies that report clinical outcomes; and studies that compare the treatment modalities, including anti-IL-17, in the English language. A total of 19 articles involving 77 cases were reviewed after applying the inclusion criteria and removing duplicates. We found that type 1 PRP was the most common condition irrespective of gender, and the trunk was the most affected area. The study showed that IL-17 inhibitors had a significant impact on the patients. However, higher-level studies are required to further evaluate the therapeutic and safety effects of the treatment.
抗白细胞介素-17A（抗IL-17A）疗法已越来越多地被用作红皮病型毛发红糠疹（PRP）的一种治疗选择。在本研究中，我们回顾了文献中所有关于该主题的现有研究，以评估抗IL-17A的疗效和安全性。我们的主要目的是评估抗IL-17A疗法在PRP治疗中疗效和安全性的当前证据。我们在PubMed、MEDLINE、Ovid、Embase和Web of Science电子数据库中检索了从创刊至2022年的相关文章。我们的纳入标准如下：随机对照试验（RCT）、半随机试验或前瞻性观察性研究，其中包括接受生物治疗的PRP患者；报告临床结果的研究；以及用英语比较包括抗IL-17在内的治疗方式的研究。在应用纳入标准并去除重复项后，共审查了19篇涉及77例病例的文章。我们发现，无论性别如何，1型PRP是最常见的情况，躯干是受影响最严重的部位。研究表明，IL-17抑制剂对患者有显著影响。然而，需要更高水平的研究来进一步评估该治疗的疗效和安全性。
